Cargando…

Obinutuzumab is Effective for the Treatment of Refractory Membranous Nephropathy

Detalles Bibliográficos
Autores principales:	Sethi, Supreet, Kumar, Sanjeev, Lim, Kathlyn, Jordan, Stanley C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486170/ https://www.ncbi.nlm.nih.gov/pubmed/32954076 http://dx.doi.org/10.1016/j.ekir.2020.06.030

Ejemplares similares

Use of obinutuzumab for refractory autoimmune thrombocytopenia secondary to CLL
por: Agrawal, Rohitashva, et al.
Publicado: (2020)

Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies
por: Kittai, Adam S., et al.
Publicado: (2021)

Membranous nephropathy associated with immunoglobulin G4-related disease successfully treated with obinutuzumab
por: Ginthör, Noemi E, et al.
Publicado: (2021)

Successful treatment of hairy cell leukemia variant with obinutuzumab
por: Al-Sarayfi, Diana, et al.
Publicado: (2021)

The Characteristics of Concurrent Anti-Glomerular Basement Membrane Nephritis and Membranous Nephropathy
por: Bu, Lihong, et al.
Publicado: (2023)

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
por: Sharman, Jeff P., et al.
Publicado: (2022)

P1080: ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY
por: Trotman, Judith, et al.
Publicado: (2023)

Successful obinutuzumab administration after rituximab discontinuation due to intolerance in patients with hematologic disorders
por: Schieber, Timothy, et al.
Publicado: (2023)

Obinutuzumab Rescue in Rituximab Resistant Mixed Cryoglobulinemia
por: Genest, Dominique S., et al.
Publicado: (2021)

Successful Use of Intravenous Immunoglobulins in an Obinutuzumab-related Acute Thrombocytopenia
por: Haage, Tobias R., et al.
Publicado: (2022)

Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases
por: Hudson, Rebecca, et al.
Publicado: (2022)

Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies
por: Pflug, Natali, et al.
Publicado: (2021)

Rituximab in Patients With Primary Membranous Nephropathy With High Immunologic Risk
por: Naik, Sachin, et al.
Publicado: (2023)

Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2022)

P1103: OBINUTUZUMAB INDUCTION AND MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINAEMIA
por: Wróbel, Tomasz, et al.
Publicado: (2023)

CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy
por: Ramachandran, Raja, et al.
Publicado: (2016)

Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
por: Kutsch, Nadine, et al.
Publicado: (2022)

Proteomic Analysis of Complement Proteins in Membranous Nephropathy
por: Ravindran, Aishwarya, et al.
Publicado: (2020)

Membranous nephropathy and carbamazepine
por: Sangeetha, B., et al.
Publicado: (2014)

Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
por: Kutsch, Nadine, et al.
Publicado: (2022)

Coxsackievirus A16 Encephalitis during Obinutuzumab Therapy, Belgium, 2013
por: Eyckmans, Tom, et al.
Publicado: (2014)

Donor-derived Cell-free DNA Combined With Histology Improves Prediction of Estimated Glomerular Filtration Rate Over Time in Kidney Transplant Recipients Compared With Histology Alone
por: Huang, Edmund, et al.
Publicado: (2020)

OA19 A case of severe refractory lupus enteritis and nephritis that remitted with Obinutuzumab
por: Chakravorty, Mithun, et al.
Publicado: (2022)

Case report: Successful treatment of refractory membranous nephropathy with telitacicept
por: Zhang, Lei, et al.
Publicado: (2023)

The clinical development of obinutuzumab for the treatment of follicular lymphoma
por: Ma, Barbara, et al.
Publicado: (2017)

Membranous nephropathy: a single disease or a pattern of injury resulting from different diseases
por: Sethi, Sanjeev
Publicado: (2021)

Membranous Nephropathy With Crescents
por: Alawieh, Rasha, et al.
Publicado: (2020)

Heterogeneity of Target Antigens in Sarcoidosis-Associated Membranous Nephropathy
por: Zubidat, Dalia, et al.
Publicado: (2023)

Obinutuzumab in connective tissue diseases after former rituximab-non-response: a case series
por: Kvacskay, Peter, et al.
Publicado: (2022)

Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study
por: Fresa, Alberto, et al.
Publicado: (2022)

Bortezomib Treatment for Refractory PLA2R-Positive Membranous Nephropathy
por: Geara, Abdallah S., et al.
Publicado: (2021)

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
por: von Tresckow, Julia, et al.
Publicado: (2022)

Evaluation of Clazakizumab (Anti–Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney Allografts
por: Jordan, Stanley C., et al.
Publicado: (2022)

The Occurrence of Richter's Syndrome during Treatment with Obinutuzumab and Chlorambucil
por: Ng, Teng Fong, et al.
Publicado: (2020)

D-penicillamine-induced membranous nephropathy
por: Kumar, R. P. Senthil, et al.
Publicado: (2014)

Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia
por: Seiter, Karen, et al.
Publicado: (2015)

The immunohistological profile of membranous nephropathy associated with syphilis infection
por: Wanderley, David Campos, et al.
Publicado: (2021)

MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial
por: Pott, Christiane, et al.
Publicado: (2019)

Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial
por: Morschhauser, Franck, et al.
Publicado: (2021)

Rituximab in Primary Membranous Nephropathy With Severe CKD
por: Naik, Sachin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0m4vubog8l214gtul0e56mvllv